

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



Sino Harbour Holdings Group Limited

漢港控股集團有限公司

(Incorporated in Bermuda with limited liability)

(Stock Code: 1663)

VOLUNTARY ANNOUNCEMENT RECOGNITION OF A SUBSIDIARY OF THE COMPANY AS MUNICIPAL HIGH AND NEW TECHNOLOGY ENTERPRISE R&D CENTRE

This announcement is made by Sino Harbour Holdings Group Limited (the “**Company**”, together with its subsidiaries, the “**Group**”) on a voluntary basis to inform its shareholders and potential investors of the latest business development of the Company.

The board of directors of the Company (the “**Directors**” and the “**Board**”, respectively) is pleased to announce that, according to the *Regulations on the Management of Hangzhou Municipal Enterprise High and New Technology R&D Centre* (Hang Ke Gao [2022] No. 39) (《杭州市企業高新技術研究開發中心管理辦法》(杭科高[2022]39號)), Hangzhou IPS Pharmaceutical Research Enterprise High and New Technology R&D Centre (杭州市美測醫藥藥物研究企業高新技術研究開發中心) of Zhejiang IPS Pharmaceutical Technology Company Limited (浙江美測醫藥科技有限公司) (“**Zhejiang IPS**”, a subsidiary of the Company) was successfully recognised as Hangzhou Municipal Enterprise High and New Technology R&D Centre after passing on-site inspection and assessment conducted by Hangzhou Municipal Science and Technology Bureau.

The recognition as Hangzhou Municipal Enterprise High and New Technology R&D Centre demonstrates that Zhejiang IPS is a large-scale high and new technology enterprise with an independent R&D centre and necessary conditions and infrastructure for technology R&D, results conversion and high and new technology industrialisation.

The Group believes that with the recognition as the municipal R&D centre, together with precise and advanced instruments and equipment in new laboratory, more comprehensive professional and technical talent and stronger R&D team, Zhejiang IPS has the capability to industrialise independently developed pharmaceutical products and to provide a full range of services covering generic drugs and innovative drugs in the drug discovery and pharmaceutical research stages.

Shareholders and/or potential investors of the Company are reminded to exercise caution when dealing in the shares of the Company.

For and on behalf of
Sino Harbour Holdings Group Limited
Wong Lam Ping
*Chairman, Chief Executive Officer,
Executive Director and General Manager*

Hong Kong, 12 August 2022

As at the date of this announcement, the Board comprises eight Directors, including four executive Directors, namely Mr. WONG Lam Ping (Chairman, Chief Executive Officer and General Manager), Mr. SHI Feng (Deputy Chairman), Mr. WONG Lui and Ms. GAO Lan; one non-executive Director, namely Mr. CHAN Kin Sang; and three independent non-executive Directors, namely Mr. XIE Gang, Mr. HE Dingding and Mr. WONG Ping Kuen.